Company profile
Healthcare, pharmaceuticals, medtech · New Brunswick, New Jersey, United States · jnj.com
Johnson & Johnson is a global healthcare company with two core businesses, Innovative Medicine and MedTech. Its current direction emphasizes pipeline-led growth, device and software-enabled care, manufacturing and technology investment, disciplined execution against long-term growth targets.
The company is framing growth around late-stage innovation, new product approvals, therapeutic-area expansion.
Q1 2026 update said it is solidifying a path to double-digit growth by the end of the decade and highlighted multiple approvals and launches.
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
It is building software-enabled surgery capabilities around connected data, analytics, AI.
Polyphonic is described as an open and secure digital ecosystem with data management, advanced analytics, edge compute, connectivity, AI capabilities.
Capital spending is being directed toward capacity, packaging, distribution, technology resilience.
The company announced more than USD 1 billion for Jacksonville and said it is part of an ongoing USD 55 billion commitment to U.S. manufacturing, R&D, technology through early 2029.
Its public posture combines cyber protection, employee controls, ethical AI principles.
The company says it has a robust information security program to safeguard networks, systems, products, information, it says AI should be used ethically under its Credo and Code.
The company is pursuing a secure, connected, data-enabled technology model, strongest in MedTech and surgical software.
Public materials emphasize secure ecosystems, edge compute, analytics, governed data platforms.
This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.
Generate a full briefYour first brief is free, no card required.
Evidence confidence 88/100. Generated 2026-07-03 from public sources.